Calgary, Alberta--(Newsfile Corp. - June 20, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta.
During business proceedings at the Meeting, shareholders elected five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:
| Votes For | Votes Withheld | Percent For | Percent Withheld | |
| Donald J. McCaffrey | 122,884,287 | 11,547,550 | 91.41% | 8.59% |
| Shawn Lu | 123,340,266 | 11,091,571 | 91.75% | 8.25% |
| Kelly McNeill | 127,204,762 | 7,227,075 | 94.62% | 5.38% |
| Siu Lun (Dicky) To | 127,856,904 | 6,574,933 | 95.11% | 4.89% |
| Kenneth Zuerblis | 129,096,743 | 5,335,094 | 96.03% | 3.97% |
Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated May 10, 2023 (the "Information Circular"). The Information Circular is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.
A webcast archive of the executive presentation portion of the Meeting will be available HERE.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary-based, late-stage, biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Our new class of epigenetic therapies are designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.
The Company's clinical program is focused on evaluating our lead candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and post COVID-19 conditions.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us:
For further information please contact:
Investor Relations
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 403-254-9252
| Last Trade: | C$0.10 |
| Daily Volume: | 4,000 |
| Market Cap: | C$28.640M |
September 03, 2024 January 11, 2024 October 04, 2023 August 29, 2023 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
